The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | VAYHIT2 primary results: ianalumab and eltrombopag versus placebo and eltrombopag in 2L primary ITP
Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, shares primary results from the VAYHIT2 trial (NCT05653219), a Phase III study evaluating the combination of eltrombopag with ianalumab, a novel anti-BAFF receptor monoclonal antibody, in patients with primary immune thrombocytopenia (ITP) in the second-line (2L) setting. Dr Al-Samkari highlights that the study demonstrated significant improvements in time-to-treatment failure and sustained response at six months in the ianalumab arm, with a favorable side-effect profile and potential for disease modification early in the disease course. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
